文献速递消化道肿瘤与早癌消化内镜

提高粪便免疫化学检测阳性阈值对结直肠癌筛查项目后续轮次检出病变的影响

Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program.
PubMed 文献 · Gastrointest Endosc · 2018-08-22

该研究纳入37,877例第一轮粪便免疫化学检测(FIT1)阴性且完成两年后第二轮FIT(FIT2)的个体,分析FIT1定量水平与FIT2阳性后病变的关系。FIT1水平越高,FIT2阳性率及进展期病变比例越高;第二轮检出51例结直肠癌,其中3例IV期患者FIT1均<20 μg Hb/g粪便。作者认为该组5.1%的结直肠癌检出率可接受,但若在首轮捕获这些病例需极高敏感性阈值,将造成不可持续的内镜转诊负担。

要点

  • FIT1<5 μg Hb/g粪便者FIT2阳性率2.3%,FIT1 40.1-45 μg Hb/g粪便者FIT2阳性率15.6%。
  • FIT1水平升高伴随结肠镜正常比例下降,进展期病变(结直肠癌+高风险腺瘤)比例从7%升至50%。
  • 第二轮检出51例结直肠癌,3例IV期患者FIT1均<20 μg Hb/g粪便。

核心结论

  • 在阳性阈值相对较高时,首轮FIT阴性者的定量水平可区分第二轮筛查中不同程度的病变检出率。
  • 该组5.1%的结直肠癌检出率似乎可接受,但在首轮捕获不可治愈病例所需阈值过于敏感,将造成不可持续的内镜转诊负担。

研究设计与样本

  • 研究纳入37,877例FIT1阴性且2年后完成FIT2的个体,分析FIT2阳性者的病变结局并与FIT1水平相关。

主要发现

  • FIT1<5 μg Hb/g粪便者FIT2阳性率2.3%,FIT1 40.1-45 μg Hb/g粪便者FIT2阳性率15.6%。
  • 结肠镜正常比例随FIT1水平升高而下降,进展期病变(结直肠癌+高风险腺瘤)比例从FIT1<5 μg Hb/g粪便的7%升至40.1-45 μg Hb/g粪便的50%。
  • 第二轮检出51例结直肠癌(22例I期、12例II期、14例III期、3例IV期),3例IV期患者FIT1均<20 μg Hb/g粪便。

关键数值与推荐

  • FIT1<5 μg Hb/g粪便者FIT2阳性率2.3%,FIT1 40.1-45 μg Hb/g粪便者FIT2阳性率15.6%。
  • FIT1<5 μg Hb/g粪便者进展期病变比例7%,FIT1 40.1-45 μg Hb/g粪便者进展期病变比例50%。
  • 该组结直肠癌检出率为5.1%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening is superior to the traditional binary fecal occult blood test. Its quantitative nature allows the investigator to choose a positivity threshold to match cost and endoscope capacity. The optimal threshold is still debated. BowelScreen, the Irish national colorectal cancer screening program, has a cut-off of 45 μg Hb/g feces, and in this study we investigated the impact of this threshold on pathology detected in round 2 in individuals who had a negative result for round 1 FIT (FIT1). METHODS: All individuals with a negative FIT1 result who completed a round 2 FIT (FIT2) 2 years later were included. Pathology outcomes for individuals who had positive FIT2 results were correlated with FIT1 levels. RESULTS: A total of 37,877 individuals had negative FIT1 results and completed FIT2. One thousand two hundred thirty (3.2%) had positive FIT2 results (702 men [57%], median age 69, age range 60-70 years). Quantitative analysis showed that at an FIT1 level <5 μg Hb/g feces, 2.3% had positive FIT2 results. At a higher cut-off of 40.1 to 45 μg Hb/g feces, 15.6% of individuals had positive FIT2 results. One thousand two (81.5%) underwent colonoscopy, with clinical outcomes in all cases. Three hundred fifty-one (35%) had normal colonoscopy results. The proportion of individuals with normal colonoscopy results decreased as FIT1 levels rose. Conversely, advanced pathology (CRC + high-risk adenomas) rates rose from 7% to 50% when FIT1 was <5 compared with 40.1 to 45 μg Hb/g feces, respectively. There were 51 screen-detected cancers in round 2 among individuals with negative FIT1 results (22 stage I, 12 stage II, 14 stage III, 3 stage IV). All 3 stage IV individuals had FIT1 results <20 μg Hb/g feces. CONCLUSIONS: Varying rates of pathology are observed in round 2 of a screening program based on the quantitative level of a negative round 1 FIT result when the positivity threshold is relatively high. A CRC rate of 5.1% within this group appears acceptable. Although patients with incurable cancer were observed, the positivity threshold to capture these cases within round 1 would have been so sensitive that it would create an unsustainable endoscopy referral burden.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Gibson DJ, Mooney T, Mooney J, et al. Impact of a higher fecal immunochemistry test cut-off on pathology detected in subsequent rounds of a colorectal screening program. Gastrointest Endosc. 2018. PMID: 30142350. doi:10.1016/j.gie.2018.08.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。